Simple, they got more cash on this PPS spike and gosh forbid these guys actually have to work.
***Each Warrant entitles the holder to purchase one share of common stock at an exercise price of $0.3333 per share from the date of issuance through its expiration 30 months from the date of issuance.***
Dont worry though, they likely will be asking you for more of your money soon enough.
I think there are two versions for the CYTX story. TAP is behind all the planning.
1. Version one. A Merge or Acquisition option from a foreign pharma with strong interest in cell therapy.
2. Version two (CYTX going solo;don't want to repeat what Hedge has said) - Hedge's previous postings. For what's worth, many traders tend to trade down the stock on spikes.
Regardless what the version will come true, the AZA acquisition is pivotal to bring in the necessary revenu. while the cell therapy business may remain small (unless version one would come).